Cookie policy

This site uses cookies to improve your user experience. By using this website, you agree that we can place cookies on your device. For further information, please read our Privacy And Cookies Policy

I accept the terms and conditions
Skip Ribbon Commands
Skip to main content

Mastering Rapid and Healthy Vascular Repair

13/01/2016 - Global

Pushing the boundaries of science and medical engineering for the improvement of health: Ultimaster combines an optimal balance between stent design for ultimate conformability with simultaneous polymer resorption and drug release, to match the procedure-triggered biological response in the vessel.(1) This results in optimal vessel recovery and potentially shortened DAPT time.(2)

Functional endothelium(3)

1 Month

2 Months

3 Months


 

86% strut coverage as early as 1 month(4)

translated into long-term safety(6)

 


 


 


 


 


 


 


 


 

 

 

 

 

 

 

(1) Data on file at Terumo Corporation (Doc nr. BioRes02-T)
(2)1 month DAPT CE Mark approved for patients in need. Patients should be maintained on clinically adequate post-procedural antiplatelet therapy according to the current guidelines. In case of need, dual antiplatelet therapy can be discontinued earlier, but not before one month. Ultimaster IFU
(3) Stojkovic S et al. Reduced sirolimus systemic exposure and improved bioresorbable polymer properties: new allies for the treatment of patients with coronary artery disease. Fundam Clin Pharmacol. 2015 Feb;29(1):95-105
(4) P. Smits et al. DISCOVERY 1TO3 - Assessment of strut coverage of biodegradable polymer DES at 1, 2 and 3 months after stent implantation by Optical Frequency Domain Imaging. Presented at EuroPCR 2015.
(5) Barbato E et al. A first-in-man clinical evaluation of Ultimaster, a new drug-eluting coronary stent system: CENTURY study. EuroIntervention. 2015 Sep 22;11(5):541-8. doi: 10.4244/EIJY14M08_06.
(6) Based on ST rates from CENTURY and CENTURY II trials, Ultimaster IFU and data on file at Terumo Corporation
(7) Saito S et al. A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: the CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients with Coronary Artery Disease) trial. Eur Heart J. 2014 Aug 7;35(30):2021-31